Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine

Next Previous
Trial Profile

A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Amgen

Most Recent Events

  • 26 Sep 2023 Status changed from discontinued to completed.
  • 10 Feb 2022 Status changed from recruiting to discontinued. Reason the study was stopped: Per Amgen Regulatory and Study Team, the study can move forward with the close out activities for the PK study since all ongoing subjects have completed based.
  • 08 Jun 2021 Planned End Date changed from 28 Dec 2021 to 26 Jun 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top